Table 2.
Mean differences in pre- and postintervention (3 months) self-reported efficacy measures with estimated effect sizesa.
| Individual statement | Baseline score, mean (SD) | Score at 3 months, mean (SD) | t test (df) | P valueb (2-tailed) | Effect size (Cohen d) | Effect size interpretationc |
| I currently have a satisfying sex life | 1.89 (0.92) | 1.90 (0.94) | 0.376 (88) | .71 | 0.01 | Insignificant |
| I have a good understanding of how to manage the impact of prostate cancer treatment on my sex life | 2.31 (0.86) | 2.57 (0.85) | 3.660 (88) | .001d | 0.517 | Medium |
| I can have a satisfying sex life despite prostate cancer treatment | 2.38 (0.79) | 3.17 (0.78) | 7.643 (88) | .001d | 1.001 | Large |
| I am comfortable discussing sexual issues with a partner | 3.08 (0.72) | 3.12 (0.7) | 0.851 (88) | .40 | 0.055 | Insignificant |
| I am comfortable discussing sexual issues with a health professional | 2.81 (0.74) | 2.82 (0.71) | 0.241 (88) | .81 | 0.014 | Insignificant |
aIndividual statements were scored on a scale between 1 and 4 points based on the response to the following: “How much do you agree with each statement?” Responses were measured on a 4-point scale anchored by strongly disagree and strongly agree at either end. Total composite scores out of 20 were calculated by combining scores from each statement. The total composite scores are as follows: mean baseline score, 12.23 (SD 2.46); mean score at 3 months, 13.62 (SD 2.31); t88=9.570; P=.001; effect size (Cohen d)=0.577; and effect size interpretation, medium.
bBonferroni-adjusted P value for multiple comparisons (P=.007).
cEffect size interpretation: 0.00-0.19 (insignificant), 0.20-0.49 (small), 0.50-0.79 (medium), and ≥0.80 (large).
dDenotes a significant pre-post intervention effect.